


Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial



Sung Hoon Noh*, Sook Ryun Park, Han-Kwang Yang, Hyun Cheol Chung, Ik-Joo Chung, Sang-Woon Kim, Hyung-Ho Kim, Jin-Hyuk Choi, Hoon-Kyo Kim, Wansik Yu, Jong Inn Lee, Dong Bok Shin, Jiafu Ji, Jen-Shi Chen, Yunni Lim, Stella Ha, Yung-Jue Bang*, on behalf of the CLASSIC trial investigators†



Number at risk
Observation alone
Adjuvant capecitabine and oxaliplatin

Time (months)	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51	54	57	60	63	66	69	72	75	78
Observation alone	515	473	460	453	443	431	415	407	395	379	369	352	344	329	316	284	247	222	194	163	137	107	81	60	33	8	0
Adjuvant capecitabine and oxaliplatin	520	481	468	461	452	439	434	426	418	405	392	382	376	369	361	333	294	246	220	200	169	126	92	67	42	11	0

The estimated 5-year overall survival 78% (95% CI 74–82) in the adjuvant CT group 69% (64–73) in the observation alone group.

	N	5-year disease-free survival			5-year overall survival		
		Adjuvant capecitabine and oxaliplatin	Observation alone	Hazard ratio	Adjuvant capecitabine and oxaliplatin	Observation alone	Hazard ratio
II	515	80% (74–85)	68% (61–74)	0.55 (0.38–0.80)	88% (83–92)	79% (73–84)	0.54 (0.34–0.87)
IIIA	377	58% (50–67)	44% (35–53)	0.61 (0.44–0.84)	70% (62–77)	63% (55–71)	0.75 (0.52–1.10)
IIIB	143	52% (40–65)	21% (9–33)	0.52 (0.33–0.82)	66% (54–78)	45% (31–58)	0.67 (0.39–1.13)

Data are % (95% CI) or hazard ratio (95% CI).

Table 3: Disease-free survival and overall survival by disease stage in the intention-to-treat population

Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis

Jae-Ho Cheong*, Han-Kwang Yang, Hyunki Kim, Woo Ho Kim, Young-Woo Kim, Myeong-Cherl Kook, Young-Kyu Park, Hyung-Ho Kim, Hye Seung Lee, Kyung Hee Lee, Mi Jin Gu, Ha Yan Kim, Jinae Lee, Seung Ho Choi, Soonwon Hong, Jong Won Kim, Yoon Young Choi, Woo Jin Hyung, Eunji Jang, Hyeseon Kim, Yong-Min Huh, Sung Hoon Noh*





Figure 2: Clinical subsets of patients with resectable gastric cancer by prognostic (A) or predictive (B) single patient classifiers

Patients are assigned to the different subgroups on the basis of expression of four classifier genes assessed with real-time RT-PCR.

Immune high (GZMB+, WARS+); low risk and no benefit
 Stem-like high (SFRP4+); high risk
 Epithelial-high (CDX1+); CTx-benefit
 No benefit relationship with SFRP4??